Amgen raises dividend 6% amid debt and drug challenges, signaling cautious future growth.

Amgen announced a 6% increase in its quarterly dividend, continuing its steady annual raises. Despite strong free cash flow and earnings coverage, the company's heavy debt from acquisitions and declining sales of legacy drugs pose challenges. The success of its obesity drug program and biosimilar competition will be key factors influencing future dividend growth. Investors should watch upcoming clinical trial results and drug sales trends to gauge the sustainability of dividend increases.

As of Sep 29, 2026 20:22 WIB, Amgen's stock on Pluang is priced at USD 417.56 with a slight 1-day decline of 0.14%. The company maintains a dividend yield of 2.41%, reflecting steady income for shareholders despite challenges noted in the article. Pluang data shows a balanced order activity with 55% of investors buying and 45% selling, indicating mixed sentiment around Amgen's future prospects.